Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« EMBL Chemical Biology: Weird Aggregating Compounds | Main | EMBL Chemical BIology: Natural Product Multiheterocycles »

September 26, 2012

EMBL Chemical Biology: Covalent Probes

Email This Entry

Posted by Derek

A short talk from Steven Verhelst of Munich went into detail on some covalent probes for rhomboid proteases. I've been interested for a while about what happens when you run small electrophilic compounds over proteins - do they stick to everything, or can they show selectivity? The canonical paper on this topic is from the Cravatt group, which I'd recommend to anyone who finds this topic worthy. (Update: the Liebler group at Vanderbilt has also published some excellent work in this area, concentrating on Cys modification). Verhelst had one variety of electrophile that was selective in the active site, and another class that inhibited by sticking all over the place. So the answer is probably "Depends on your protein, and on your electrophile. Try it and see".

Comments (6) + TrackBacks (0) | Category: Chemical Biology


COMMENTS

1. Sam on September 26, 2012 11:36 AM writes...

Sure, the Cravatt paper was great, but an earlier paper by Dan Liebler addresses some of these issues too - Chem. Res. Toxicol. 2008,21,2361.

Permalink to Comment

2. barry on September 26, 2012 11:48 AM writes...

In the context of drug discovery, we usually want to break out the covalent binders in reversible and irreversible. Peptide nitriles form covalent thioimidates reversibly in cysteine-protease active sites. Likewise peptide aldehydes and alpha-keto-amides form reversible covalent tetrahedral adducts in serine proteases. These seem less worrisome than irreversible covalent adducts formed from e.g. iodoacetamide.
Of course, if the off-rate of a reversible binder is comparable to the working life of the target protein, the question may be moot.

Permalink to Comment

3. Imaging guy on September 26, 2012 1:29 PM writes...

According to Dan Liebler (if I understand correctly) covlanet binding is dangerous. Others say it is not necessarily so. E.g. "The resurgence of covalent drugs" in "NATURE REVIEWS DRUG DISCOVERY, 2011". Your opinions?

Permalink to Comment

4. anonymous on September 26, 2012 7:29 PM writes...

Based on personal (scientific) experience, I think selective (key word) irreversible inhibitors make GREAT proof of concept molecules

Permalink to Comment

5. Ramesh Sistla on September 27, 2012 1:20 AM writes...

May be both reversible and irreversible inhibitors should be characterized by their residence times. An irreversible inhibitor could be treated like a reversible one with a longer residence time. There are examples of irreversible inhibitors which 'fall off' faster than a reversible inhibitor. While it is a good idea from a mechanism perspective to know whether a certain inhibitor forms an adduct or not, from a drug discovery point of view we could do well to characterize the residence times (may not easy to do in all cases though).

Permalink to Comment

6. RJH on September 30, 2012 9:15 AM writes...

Before getting too worked up about whether or not covalent binders are worthwhile avenues to develop, note that Derek's tagline mentions this work as covalent PROBES. Probe compounds aren't always meant to be drugs (i.e. ADME PK characteristics to go forward to market), just selective molecules used to tease out biological target mechanistic information and the like.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
The Smallest Drugs
Life Is Too Short For Some Journal Feeds
A New Look at Phenotypic Screening
Small Molecules - Really, Really Small
InterMune Bought
Citable Garbage
The Palbociclib Saga: Or Why We Need a Lot of Drug Companies
Why Not Bromine?